Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1984 1
1985 1
1987 1
1989 2
1990 1
1993 4
1996 2
1997 5
1998 1
1999 1
2000 4
2001 3
2002 6
2003 3
2004 3
2005 6
2006 6
2007 7
2008 11
2009 13
2010 6
2011 9
2012 11
2013 10
2014 7
2015 12
2016 15
2017 18
2018 21
2019 23
2020 30
2021 28
2022 32
2023 31
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for single titan
Your search for Qingle Tian retrieved no results
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin.
Foster DS, Januszyk M, Delitto D, Yost KE, Griffin M, Guo J, Guardino N, Delitto AE, Chinta M, Burcham AR, Nguyen AT, Bauer-Rowe KE, Titan AL, Salhotra A, Jones RE, da Silva O, Lindsay HG, Berry CE, Chen K, Henn D, Mascharak S, Talbott HE, Kim A, Nosrati F, Sivaraj D, Ransom RC, Matthews M, Khan A, Wagh D, Coller J, Gurtner GC, Wan DC, Wapnir IL, Chang HY, Norton JA, Longaker MT. Foster DS, et al. Cancer Cell. 2022 Nov 14;40(11):1392-1406.e7. doi: 10.1016/j.ccell.2022.09.015. Epub 2022 Oct 20. Cancer Cell. 2022. PMID: 36270275 Free PMC article.
CAFs were once thought to be a relatively uniform population of matrix-producing cells, but single-cell RNA sequencing has revealed diverse CAF phenotypes. Here, we further probed CAF heterogeneity with a comprehensive multiomics approach. ...
CAFs were once thought to be a relatively uniform population of matrix-producing cells, but single-cell RNA sequencing has revealed d …
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
We aimed to examine the safety and activity of nivolumab induction and high-dose ipilimumab as an immunotherapeutic boost as a second-line treatment for patients with metastatic urothelial carcinoma. METHODS: TITAN-TCC is a multicentre, single-arm, phase 2 trial don …
We aimed to examine the safety and activity of nivolumab induction and high-dose ipilimumab as an immunotherapeutic boost as a second-line t …
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Peyvandi F, et al. N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533. N Engl J Med. 2016. PMID: 26863353 Free article. Clinical Trial.
METHODS: Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interaction between ultralarge von Willebrand factor multimers and platelets. ...
METHODS: Caplacizumab, an anti-von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interac …
Code ICH: A Call to Action.
Li Q, Yakhkind A, Alexandrov AW, Alexandrov AV, Anderson CS, Dowlatshahi D, Frontera JA, Hemphill JC, Ganti L, Kellner C, May C, Morotti A, Parry-Jones A, Sheth KN, Steiner T, Ziai W, Goldstein JN, Mayer SA. Li Q, et al. Stroke. 2024 Feb;55(2):494-505. doi: 10.1161/STROKEAHA.123.043033. Epub 2023 Dec 15. Stroke. 2024. PMID: 38099439 Review.
For decades, randomized trials aimed at decreasing hematoma expansion through single interventions have failed to meet their primary outcomes of statistically significant improvement in neurological outcomes. ...
For decades, randomized trials aimed at decreasing hematoma expansion through single interventions have failed to meet their primary …
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Esteban E, Barthélémy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L; TITAN-RCC study group. Grimm MO, et al. Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13. Lancet Oncol. 2023. PMID: 37844597 Clinical Trial.
We aimed to examine the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab combination as an immunotherapeutic boost after no response to nivolumab monotherapy in patients with intermediate-risk and poor-risk clear-cell metastatic renal cell carcinoma. MET …
We aimed to examine the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab combination as an immunotherapeutic boost …
Integrated spatial multiomics reveals fibroblast fate during tissue repair.
Foster DS, Januszyk M, Yost KE, Chinta MS, Gulati GS, Nguyen AT, Burcham AR, Salhotra A, Ransom RC, Henn D, Chen K, Mascharak S, Tolentino K, Titan AL, Jones RE, da Silva O, Leavitt WT, Marshall CD, des Jardins-Park HE, Hu MS, Wan DC, Wernig G, Wagh D, Coller J, Norton JA, Gurtner GC, Newman AM, Chang HY, Longaker MT. Foster DS, et al. Proc Natl Acad Sci U S A. 2021 Oct 12;118(41):e2110025118. doi: 10.1073/pnas.2110025118. Proc Natl Acad Sci U S A. 2021. PMID: 34620713 Free PMC article.
We employ a stented wound model that recapitulates human tissue repair kinetics and multiple Rainbow transgenic lines to precisely track fibroblast fate during the physiologic response to skin injury. Through integrated analysis of single cell chromatin landscapes and gene …
We employ a stented wound model that recapitulates human tissue repair kinetics and multiple Rainbow transgenic lines to precisely track fib …
TITAN: An end-to-end data analysis environment for the Hyperion imaging system.
Thirumal S, Jamzad A, Cotechini T, Hindmarch CT, Graham CH, Siemens DR, Mousavi P. Thirumal S, et al. Cytometry A. 2022 May;101(5):423-433. doi: 10.1002/cyto.a.24535. Epub 2022 Jan 28. Cytometry A. 2022. PMID: 35060322 Free article.
TITAN is implemented as an extension within the publicly available 3D Slicer software. ...Compared with current IMC analysis methods, TITAN provides a user-friendly, efficient single environment to accurately visualize, segment, and analyze IMC data for all u …
TITAN is implemented as an extension within the publicly available 3D Slicer software. ...Compared with current IMC analysis methods, …
Enabling single-site laparoscopy: the SPORT platform.
Seeliger B, Diana M, Ruurda JP, Konstantinidis KM, Marescaux J, Swanström LL. Seeliger B, et al. Surg Endosc. 2019 Nov;33(11):3696-3703. doi: 10.1007/s00464-018-06658-x. Epub 2019 Jan 8. Surg Endosc. 2019. PMID: 30623255 Free PMC article.
BACKGROUND: The Single Port Orifice Robotic Technology (SPORT) Surgical System by Titan Medical Inc. is designed to overcome the inherent challenges of minimally invasive single-access procedures. ...This preliminary feasibility experience is promising and en …
BACKGROUND: The Single Port Orifice Robotic Technology (SPORT) Surgical System by Titan Medical Inc. is designed to overcome t …
Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
Titan AL, Norton JA, Fisher AT, Foster DS, Harris EJ, Worhunsky DJ, Worth PJ, Dua MM, Visser BC, Poultsides GA, Longaker MT, Jensen RT. Titan AL, et al. JAMA Netw Open. 2020 Nov 2;3(11):e2024318. doi: 10.1001/jamanetworkopen.2020.24318. JAMA Netw Open. 2020. PMID: 33146734 Free PMC article.
OBJECTIVE: To evaluate the outcome of patients who underwent surgery for locally aggressive PNETs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective single-center case series reviewed consecutive patients who underwent resection of T3/T4 PNETs at a single academ …
OBJECTIVE: To evaluate the outcome of patients who underwent surgery for locally aggressive PNETs. DESIGN, SETTING, AND PARTICIPANTS: This r …
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Fava M, et al. Mol Psychiatry. 2020 Jul;25(7):1592-1603. doi: 10.1038/s41380-018-0256-5. Epub 2018 Oct 3. Mol Psychiatry. 2020. PMID: 30283029 Free PMC article.
A range of IV ketamine doses were compared to active placebo in the treatment of adult TRD over a 3-day period following a single infusion over 40 min. This was an outpatient study conducted across six US academic sites. ...Following a washout period, 99 eligible subjects …
A range of IV ketamine doses were compared to active placebo in the treatment of adult TRD over a 3-day period following a single inf …
326 results